Boehringer Ingelheim Strengthens Obesity Pipeline as Potential First-in-Class Triple Receptor Agonist BI 3034701 Enters Phase II Development

Дата публикации: 16-07-2026 22:07:07

Ingelheim, Germany, July 16, 2026 -- Boehringer Ingelheim today announces the start of a Phase II clinical trial evaluating its investigational triple GLP-1/GIP/NPY2 receptor agonist, BI 3034701, in patients with obesity and overweight.1 The...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Lilly's Triple Agonist, Retatrutide, Successful in Two Additional Phase 3 Obesity Trials, Delivering Significant Improvements in Weight and A1C	0	13.62	23-07-2026
2	BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1	0	20.6	22-07-2026
3	BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1	0	19.89	12-05-2026
4	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
5	New weight loss pill beats oral Ozempic in major trial	0	9.35	07-07-2026
6	Scientists solve the mystery of a brain “switch” that can trigger weight loss in opposite ways	0	6.34	15-08-2026
7	New GLP-1 diabetes pill delivers major weight loss and blood sugar control	0	6.91	15-06-2026
8	Beyond the Jab: The Surprising New Frontiers of GLP-1 Therapy	0	14.13	24-07-2026
9	Таблетка вместо уколов: новый препарат от ожирения показал снижение веса более чем на 12%	1	10.38	12-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 13.34. Источник: www.drugs.com.